A phase 1/2 study of REGN7075 in combination with cemiplimab (cemi) in patients (pts) with advanced solid tumors: Efficacy and safety results

  • Neil Howard Segal
  • , Eugenia Girda
  • , Davendra Sohal
  • , Nehal J. Lakhani
  • , Anthony J. Olszanski
  • , Lawrence Fong
  • , Michael David Kinnaman
  • , Hyunsil Han
  • , Dimitris Skokos
  • , Kerry A. Casey
  • , Ju An Wang
  • , Bei Wang
  • , Yi Hao
  • , Siyu Li
  • , Samit Ganguly
  • , Israel Lowy
  • , Frank A. Seebach
  • , Melissa Divya Mathias
  • , Melissa Lynne Johnson

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Fingerprint

Dive into the research topics of 'A phase 1/2 study of REGN7075 in combination with cemiplimab (cemi) in patients (pts) with advanced solid tumors: Efficacy and safety results'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science